Physician

Hazem Alhourani, M.D.

According to 2025 Medicare claims, Hazem Alhourani, M.D. (NPI: 1851574206) practices internal medicine in the Saginaw, MI market, with the plurality of this provider's patient population coming from Saginaw, MI. This provider's primary affiliated billing organization is DIALYSIS ASSOCIATES, P.C. (NPI: 1467549618; TIN: 382354912) and primary practice location at 48604-2839. Alhourani is affiliated with the POM ACO (ACO ID: A1297), McLaren High Performance Network, LLC (ACO ID: A3317), and Mosaic ACO (ACO ID: A5033), participating under the MSSP model.

Alhourani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 380 traditional Medicare patients, billed 1,296 HCPCS/CPT codes, and received $158,859 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,261 prescription claims across 364 beneficiaries totaling $300,460 in drug costs, led by Ozempic (Semaglutide). 2023 DME data shows 22 claims. Open Payments data shows 14 records totaling $311. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $4,232 to $300,460. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $162 to $1,671.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	214	375	$34,882
2016	507	2,582	$183,408
2017	535	2,335	$186,048
2018	568	2,041	$200,048
2019	628	2,707	$246,642
2020	477	1,986	$195,433
2021	360	1,604	$175,940
2022	461	1,695	$174,059
2023	389	1,410	$174,307
2024	380	1,296	$158,859

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	32	80	$4,232
2016	87	324	$94,921
2017	143	637	$113,302
2018	201	884	$128,787
2019	257	1,217	$106,702
2020	235	1,431	$95,711
2021	271	1,780	$91,278
2022	319	2,009	$81,309
2023	367	2,274	$164,057
2024	364	2,261	$300,460

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$137
2016	N/R	15	$86
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	68	$3,675
2020	N/R	52	$2,983
2021	N/R	34	$1,471
2022	N/R	50	$1,675
2023	N/R	22	$1,671
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	71	72	$130
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	61	89	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	73	156	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	93	141	$59
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	148	334	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	13	518	$11,725
Sevelamer Carbonate	Sevelamer Carbonate	49	3,747	$10,901
Calcitriol	Calcitriol	359	25,251	$7,164
Tacrolimus	Tacrolimus	20	780	$4,092
Amlodipine Besylate	Amlodipine Besylate	227	18,877	$2,255

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	14	$311	Travere Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Hazem Alhourani, M.D.?

Tedicare shows public-source Medicare data for Hazem Alhourani, M.D. (NPI 1851574206), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hazem Alhourani, M.D. have ACO affiliation data?

Hazem Alhourani, M.D. is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297), McLaren High Performance Network, LLC (MSSP, ACO ID A3317), and Mosaic ACO (MSSP, ACO ID A5033).

What billing organization is linked to Hazem Alhourani, M.D.?

Hazem Alhourani, M.D. is linked to DIALYSIS ASSOCIATES, P.C. (billing NPI 1467549618) in the available physician profile data.

Does Hazem Alhourani, M.D. have Open Payments data?

Hazem Alhourani, M.D. has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.